Program
RO7268489
A development code.
Its studies are mostly in Multiple Sclerosis, Chronic Progressive, led by Hoffmann-La Roche.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 11 open or running | phase 2since Dec 5, 2025 | Dec 5, 2025 | May 30, 2028phase 2 · NCT07282574 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 5, 2025First study: phase 2 study in Multiple Sclerosis, Chronic ProgressiveFirst studyNCT07282574 · 360 planned · Australia, Brazil, France and more
Ahead
- May 30, 2028Primary completion: phase 2 study in Multiple Sclerosis, Chronic ProgressiveNCT07282574
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07282574Multiple Sclerosis, Chronic Progressive · Australia, Brazil, France and more | 2 | Recruiting | May 30, 2028 | 360 |
How it is read
Names in the registry
- “RO7268489”, 1 entry
Codes read as this program: RO7268489.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.